The Tie gene encodes an endothelial cell receptor tyrosine kinase necessary for normal vascular development. The Tie gene promoter targets expression of heterologous genes specifically to endothelial cells in transgenic mice. Here we have characterized the promoter sequences critical for endothelial cell-specific activity in cultured cells and transgenic mice. Progressive deletions and site-directed mutations of the promoter showed that the critical endothelial cell-specific elements are an octamer transcription factor binding site and several Ets binding sites located in two clusters within 300 bp upstream of the major transcription initiation site. Among members of the Ets transcription factor family tested, NERF-2 (a novel transcription factor related to the ets factor ELF-1), which is expressed in endothelial cells, and ETS2 showed the strongest transactivation of the Tie promoter; ETS1 gave lower levels of stimulation and the other Ets factors gave little or no transactivation. Furthermore, the Tie promoter directed the production of high amounts of human growth hormone into the circulation of transgenic mice. The secreted amounts correlated with transgene copy number, being relatively insensitive to the effects of the transgene integration site. These properties suggest that Tie promoter activity is controlled by endothelial cell Ets factors and that it has potential for use in vectors for endothelial cell-specific gene expression.-Iljin, K., Dube, A., Kontusaari, S., Korhonen, J., Lahtinen, I., Oettgen, P., Alitalo, K. Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. FASEB J. 13, 377-386 (1999) 
Endothelial cells play a critical role in the formation of the circulatory system as well as in the physiological and pathological functions of the vascular system (1) . As endothelial cells line the lumens of blood vessels, they form a potentially useful target for gene therapy vectors for several reasons. First, endothelial cells provide a readily accessible compartment for the transfection of gene constructs, because vectors injected into the bloodstream are in potential contact with all endothelial cells within minutes. Second, virtually all cells in tissues are located within 20 m from endothelial cells, facilitating the delivery of endothelial cell secreted proteins to various other cell types. Third, in tumors, endothelial cells represent a diploid population of stromal cells necessary for the growth of solid tumors beyond a few millimeters in size.
In contrast to cells contributing to the skeletal muscle and hematopoietic lineages, little is known about the mechanisms of differentiation and maturation of endothelial cells. Regulatory regions of several endothelial cell-specific genes have been identified and partially characterized only recently (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The promoter elements controlling endothelial-specific gene expression are of special interest because they may be useful in making targeting vectors for gene therapy directed against angiogenesis associated with tumors or other disease processes involving the vascular system. Tie (tyrosine kinase with immunoglobulin and epidermal growth factor homology domains) 2 was the first one of the five receptor tyrosine kinases found to be endothelial cell specific (14) . To understand the molecular mechanisms underlying specific expression of genes in endothelial cells, we have studied the elements that control Tie transcription.
Tie has an essential role in the development of the vascular system. It is first expressed on embryonic day 8.5 (E8.5) in angioblasts of the head mesenchyme, in endothelial cells of the dorsal aorta, and in the blood islands of the yolk sac, and continues in endothelial cells throughout embryogenesis (15) . Expression of Tie is down-regulated in many adult tissues after development, but in those where it persists, it is endothelial cell-specific (15) . However, Tie mRNA is enhanced in the endothelium of adult mice at sites of neovascularization associated with corpus luteum formation during the menstrual cycle and with wound healing (16) . Increased levels of Tie mRNA and protein have also been found in some pathological conditions such as in the vasculature of certain tumors, suggesting that Tie is needed for tumor angiogenesis (17, 18) . To date, no ligand for Tie has been identified, but it is possible that Tie modulates angiopoietin signals via the related Tek/ Tie-2 receptor (19) .
The promoters of both human and mouse Tie gene have been isolated and partially characterized (4) . Neither promoter contains classical promoter elements such as TATA or CAAT boxes. Significant homology between the mouse and human promoters was seen in the region of about 0.9 kb upstream of the translational initiation codon. This promoter region contains conserved putative binding motifs for transcription factors conforming to Ets, AP-2, a conserved octamer factor binding DNA element, and GT repeat sequences, also described in the mouse Tek/Tie-2 endothelial-specific enhancer (10) . The 0.8 kb AflII-ApaI fragment of the mouse Tie promoter containing all these elements could target gene expression specifically to endothelial cells in vivo, indicating that the elements relevant for endothelial cell specificity are contained within this fragment (4).
Our aim was to determine which of these elements are required for the activity and cell type specificity of the mouse Tie promoter. Mutations were made to the promoter by site-directed mutagenesis, and activities of the mutant promoters were tested both in vitro and in vivo by using reporter gene constructs. In this study, the Tie promoter showed endothelial cell-specific activity in transfected cells. Mutations made to the octamer region and to the Ets binding sites strongly decreased promoter activity in vitro. The results from transgenic embryos showed that all the sequences necessary for endothelial-specific expression are within a 333 bp region, which contains several putative binding sites for Ets-factors and the octameric sequence.
MATERIALS AND METHODS

Ribonuclease protection assay
The mouse RNA antisense probes of 324 bp and 263 bp were generated from plasmids containing a 0.8 kb AflII-BamHI or a 1.1 kb HindIII-ApaI fragment (sites shown in Fig. 1 ). The plasmids were linearized by Bg l II digestion and labeled using T7 polymerase and [␥-32P]UTP. Twenty micrograms of poly(Aϩ) RNA were incubated with labeled probe at 50°C overnight. Unhybridized RNA was digested with RNAse A (10 U/ml) and T1 (1 g/ml) at 37°C for 15 min and the samples were analyzed in 8% sequencing gels.
Primer extension analysis
Primer extension analysis was carried out using the AMV reverse transcriptase primer extension system (Promega, Madison, Wis.). A synthetic oligonucleotide complementary to the 5Ј end of mouse Tie cDNA (5Ј-ACTTACCAACAT-GAGAGGCCAAGAAAAGAGTG-3Ј) was labeled according to the manufacturer's protocol. The primer (10 pmol) was incubated with 1ϫ forward exchange buffer, 10 Ci/ml [␥-32P]ATP, and 10 U T4 polynucleotide kinase at 37°C for 1 h. The kinase was inactivated by heating at 90°C for 2 min and the labeled primer was ethanol precipitated.
About 20 g of poly(Aϩ) RNA and 5 ϫ 10 5 cpm of labeled primer were annealed in hybridization buffer (40 mM Pipes, pH 6.4, 1 mM EDTA (pH 8.0) 0.4 M NaCl and 80% formamide) by heating at 95°C for 12 min, cooled slowly to room temperature, and ethanol precipitated. The dried annealing mixture was suspended in primer extension buffer (50 mM Tris-HCl, pH 8.3, at 42°C, 50 mM KCl, 10 mM MgCl 2 , 10 mM DTT, 2 mM each dNTP and 0.5 mM spermidine), and RNA isolated from 12 day p.c. mouse embryos and adult kidneys was analyzed by RNase protection using the labeled cRNA transcribed from the indicated fragments as templates; protected fragments were analyzed in gel electrophoresis. B) Results of primer extension analysis using the same RNAs and the primer specified in Materials and Methods (arrow). The lengths of the fragments are indicated in nucleotides (nt).
20 U RNasin and 40 U AMV reverse transcriptase were added. After a 2 h incubation at 42°C, template RNA was digested by 20 g/ml RNAse A in 100 mM NaCl, 10 mM Tris-HCl, and 1 mM EDTA (pH 7.5) at 37°C for 15 min. The mixture was phenol extracted and ethanol precipitated; the pellet was resuspended in loading dye (98% formamide, 10 mM EDTA, 0.1% xylene cyanol, and 0.1% bromophenol blue) and loaded to a 9% acrylamide/7 M urea gel. After electrophoresis, the dried gels were autoradiographed for 2-4 days.
Plasmids and mutagenesis
In transfection assays of cultured cells, the promoter activities were analyzed using luciferase reporter gene constructs. Deletions of the AflII-ApaI promoter fragment in the pGL2 reporter vector were made using the appropriate primers and polymerase chain reaction (PCR), followed by recloning to the same vector and confirmed by sequencing. pGL3 basic and control vectors contained the firefly luciferase gene without promoter and driven by the SV40 promoter/enhancer, respectively. Additional deleted and mutant fragments of the mouse Tie promoter were inserted into the pGL3 basic vector. Schematic pictures of the resulting constructs appear in Fig. 2 and Fig. 3A . For site-directed mutagenesis, the 1.2 kb HindIII-BamHI fragment of mouse Tie promoter containing the AflII-ApaI fragment, which was previously shown to be endothelial cell specific in vivo (4), was cloned to the pALTER site-directed mutagenesis vector. Because this fragment contains the translational initiation codon (ATG) of the Tie open reading frame, an NcoI site was introduced the sequence GT ATG G by using the Altered Sites II in vitro mutagenesis system (Promega) and the primer 5Ј-TCCCCACCAGACC ATG GTCTGGAAGCTGCCCT-3Ј. The ATG codon embedded in the NcoI site (CC ATG G), would then be in the correct reading frame with the luciferase open reading frame of the pGL3 vector.
Upstream deletions of the GT repeat sequences and the Ets1 site were similarly made using primers 5Ј-TGAGAAG-GTTTGGAGGCAGGACATTGTTCTTTTTACTGAGATTTT-ATTATGTTGTTATCT-3Ј and 5Ј-CACGGGAGACAGGAAA-GGGAGGAAGCCAGTTGAGCACTTACAGTTCTCTGACTA-AC GGTC-3Ј, respectively. Mutations were also made to the 3Ј cluster of Ets sites (primer 3Ј-CCTCGGTGCTGGGGATTAA-GATTAAATGATGGTTAGGG-3Ј), the 5Ј cluster (primer 5Ј-ACGGGAGACAGGAAATTGATTAAGCCAGTGGCTTCC-3Ј), the octamer binding sequence (primer 5Ј-AGGTTGTGA-CAAGGACGCGTCTGGGGATGGTTGG-3Ј), and the AP-2 binding sequence (primer 5Ј-TTTTGGCGTCTTCCATG-GTCTGGAAGCTGCCACCTCGGTGCTGGGGAGGAAGA-GGAAATG-3Ј) using as template the HindIII-NcoI fragment with a deletion of the GT repeat sequences. These latter mutations were made by using the GeneEditor in vitro mutagenesis kit (Promega). All constructs were confirmed by sequencing and named according to the mutated DNA sequences (see Fig. 3A ).
For studies in transgenic mouse embryos, HindIII-NcoI digested Tie promoter fragments were ligated to the pSDKLacZpA reporter vector (a kind gift from Dr. Janet Rossant, Mount Sinai Research Institute, Toronto, Canada; see ref 20) containing the ␤-galactosidase open reading frame, followed by a simian virus 40 poly(A) addition sequence.
Cell culture and transfection assays
Mouse lung endothelial cells (LE-II; ref 21 ) and brain endothelial cells (BEND; ref 22) were grown in minimal essential medium (MEM) and NIH3T3 murine fibroblasts in Dulbecco's modified Eagles' medium (DMEM) containing 10% fetal calf serum and antibiotics. Mouse keratinocytes (MK-2) were grown in low (2 mM) CaCl 2 MEM containing 10% fetal calf serum, antibiotics, and epidermal growth factor (4 ng/ml). The spontaneously immortalized human umbilical vein endothelial cells (ECV304, 23) were grown in Media 199. The human embryonic kidney cells (HEK293, ATCC) and the murine endothelial cell line PY41 (24) were grown in DMEMsupplemented 10% fetal bovine serum and antibiotics, as described previously (25) .
LE-II, BEND, NIH3T3, and MK-2 cells were transfected by the calcium phosphate-mediated transfection method. The minimal amount of plasmid registering full transcriptional activity was titrated prior to the experiments. In subsequent cases, 5 g of the appropriate reporter construct was transfected along with 0.2 g of pRL-TK to correct for variability in transfection efficiency. The pRL-TK vector contains the herpes simplex virus thymidine kinase promoter region upstream of the renilla luciferase gene. Cell extracts were prepared 48 h after transfection in the passive lysis buffer (Promega). Luciferase activity was measured using Digene DCR-1 luminometer and Promega Dual Luciferase Assay System.
The ratio of firefly luciferase activity to renilla luciferase activity in each sample served as a measure of the normalized luciferase activity, which was divided by the activity of the pGL3 control vector and expressed as relative luciferase activity. Each construct was transfected at least five times, and data for each construct are presented as the mean Ϯse. Relative luciferase activity among constructs was compared by a factorial analysis of variance, followed by the Student's t test. Statistical significance was accepted at P Ͻ0.05.
Cotransfections of 1.5-2 ϫ 10 5 ECV and HEK293 cells were performed using 1.75 g of the reporter gene construct DNA and 0.75 g of the expression vector DNA with 6.25 l of lipofectamine (Gibco BRL, Paisley, U.K.). Cells were washed with serum-free DMEM. A total of 0.8 ml of serum-free DMEM was added per well. Liposomes were incubated with the DNA in 200 l of serum-free DMEM for 15 min at room temperature and then with the cells for 4 h at 37°C. One milliliter of DMEM containing 20% fetal calf serum was added; the cells were harvested 16 h after transfection and assayed for luciferase (26) . Transfections with the PY41 cells were performed similarly, but in Optimem. Minimally, transfections were in duplicate or triplicate with similar results. Cotransfection of a second plasmid for determination of transfection efficiency was omitted because potential artifacts with this technique have been reported (27) and because many commonly used viral promoters contain potential binding sites for Ets factors.
Production and analysis of Tie promoter-LacZ embryos
The transgene was isolated from the pSDKLacZpA vector by Sa l I digestion and transgenic embryos were produced by microinjection. The injected C57/B16 ϫ DBA/2 zygotes were transferred into the oviducts of pseudopregnant CD 1 foster mothers. Embryos were stained on day 11.5 and were genotyped by PCR analysis of yolk sac and amnion DNA prepared by the salt precipitation method (28), using a primer that annealed within the Tie promoter (5Ј-AGGGAGAGAGGGT-GGGAAG-3Ј) and another one specific for the multiple cloning site of the SDKLacZpA vector (5Ј-GCTCTAGAAC-TAGTGGATC-3Ј).
Whole embryos were rinsed with phosphate buffer (0.1 M Na 2 HPO 4 , 0.1 M NaH 2 PO 4 , pH 7.3), fixed in 0.2% glutaraldehyde, 5 mM EGTA, 2 mM MgCl 2 in phosphate buffer for 20 min, washed three times for 15 min with the washing buffer (2 mM MgCl 2 , 0.01% desoxycholate, 0.02% Nonidet 40 in phosphate buffer), and stained in 5-bromo-4-chloro-3-indolyl ␤-D-galactopyranoside for 1 day. After staining, embryos were incubated in washing buffer for 1 day, postfixed with 4% paraformaldehyde for 1 day, and dried with methanol. Embryos were embedded with paraffin; 7 m sections were cut and counterstained with nuclear fast red.
Production and analysis of Tie promoter-hGH transgenic mice
The AflII-ApaI fragment of the mouse Tie promoter was cloned into the pO ͞ GH vector (Nichols Institute, Los Angeles, Calif.) upstream of the human growth hormone (hGH) cDNA. The transgene was isolated by EcoRI-XbaI digestion. DNA was extracted from mouse tail samples by the salt precipitation method. Positive pups were screened by PCR using primers annealing to human Tie promoter (5Ј-GAGA-CAGGGGATGGGAAAAA-3Ј) and to the hGH cDNA (primer 5Ј-AATGGTTGGGAAGGCACTGC-3Ј). The copy number of the transgene was studied by Southern blotting. DNA samples were digested with AvaI enzyme, and the labeled BglII-ApaI fragment of the Tie promoter was used as the probe. Blood samples were taken twice from mice at the age of 8 and 10 months. The hGH concentration was determined by a clinical hGH immunoradiometric assay. Serum from a wild-type mouse was used as a negative control.
RESULTS
Identification of the Tie RNA transcription initiation sites
RNase protection and primer extension of poly(Aϩ) RNA were used to determine the transcription initiation sites of the mouse Tie gene. RNase protection using the BglII-BamHI riboprobe produced a doublet of bands migrating at the 104 bp from RNA isolated from 12 day p.c. mouse embryonic and adult kidney RNAs (Fig. 1A) . RNase protection with a 54 nucleotide shorter BglII-ApaI riboprobe produced correspondingly shorter fragments from the same RNAs. The 5Ј end of the 104 nt and 50 nt fragments corresponded to the 5Ј end of a 155 nt product, obtained by primer extension analysis from both embryonic and kidney RNAs (Fig. 1B) .
Activity of the Tie promoter in cultured endothelial and nonendothelial cells
To define the minimal sequences of the mouse Tie promoter responsible for its activity, deletions were made to the AflII-ApaI promoter fragment found to direct endothelial cell-specific expression in transgenic mice (4). The deleted fragments were cloned into the luciferase reporter vector, transfected to LE-II mouse endothelial cells, and the cell extracts were later assayed for luciferase activity. Figure 2 shows the deletions schematically and relative promoter activities of the constructs. A 86 bp deletion of the 3Ј sequences of the AflII-ApaI fragment, including the major transcription initiation sites, abolished all promoter activity. A promoter deleted of the 541 bp AflII-BglII fragment from the 5Ј end yielded nearly one-third the activity of the strong Rous sarcoma virus promoter used as a positive control. A further 3Ј deletion of the 86 bp from the BglII-ApaI fragment abolished this activity, whereas minimal activity was registered in a construct truncated at the RNA initiation sites. Only minimal promoter activity was recovered upon deletion of 96 bp of the 5Ј sequences from the BglII-ApaI fragment.
Further mutations were made to the promoter region by site-directed mutagenesis (see Fig. 3A ). Although previous analysis showed that Tie expression is restricted to endothelial cells in vivo, Tie promoter activity was found both in endothelial cells and cervical carcinoma cells in culture (4) . To determine whether a cell culture system is suitable for studying endothelial cell-specific elements of the Tie promoter constructs, we carefully compared promoter activity in endothelial and nonendothelial mouse cells. The results of this analysis are shown in Fig. 3B . In LE-II and BEND mouse endothelial cells, the 1.1 kb HindIII-NcoI Tie promoter fragment showed 42% and 70% of the activity, respectively, of the SV40 promoter construct used as the positive control. In NIH3T3 fibroblasts and MK-2 epithelial cells, the promoter was also active but at a markedly lower level (12 and 7%, respectively, of the SV40 promoter/enhancer), indicating that the activity of the promoter is relatively specific for endothelial cells. The deletion of an upstream 0.6 kb fragment, including the GT repeats (Fig. 3A) , reduced significantly the promoter activity in BEND cells, whereas in LE-II cells the activity was somewhat increased (Fig. 3B) . Additional deletion of the upstream Ets binding site resulted in an ϳ10% decrease of promoter activity in both cell types when compared to the GT-deleted construct.
To further analyze the promoter, the individual transcription factor consensus DNA binding sites in the mTie prom-GT construct were subjected to sitedirected mutagenesis as described in Materials and Methods and in Fig. 3A . Mutation of the P1 doublet of Ets sites or the octamer sequence resulted in about a 60% reduction of the activity in both endothelial cell lines. The AP-2 site was also essential for strong Tie promoter activity in the endothelial cells in comparison with the ϪGT construct. Mutation to the P2 doublet of Ets sites just upstream of the major transcription initiation site had the strongest effect on promoter activity, reducing the activity by 83% in LE-II cells and by about 92% in MK-2 cells. Mutations affecting Tie promoter activity only in nonendothelial cells were not found.
Ets factor transactivation
Because a number of Ets binding sites are conserved between the mouse and human Tie promoters, we compared the ability of seven transcription factors of the Ets family to transactivate the promoter in human and murine endothelial cells (Fig. 4) . In human ECV endothelial cells, Tie promoter activity increased only between 1.5-and 3-fold upon cotransfection with expression vectors for the NERF-2, ETS1, and ETS2 transcription factors, whereas no stimulation was obtained with other Ets factors tested (data not shown). To avoid the possible high endogenous background caused by Ets factors such as NERF-2, which are expressed in endothelial cells, the human embryonic kidney cell line HEK293 was used in a subsequent experiment. In these cells, NERF-2, ETS1, and ETS2 were able to transactivate the Tie promoter constructs by about 8.5-, 4-, and 3-fold, respectively, whereas TEL, SAP, NERF-1, and ELK yielded little or no activity (Fig. 4A) .
Deletion of the GT-rich region and the upstream Ets consensus binding site reduced the degree of NERF-2-and ETS1-specific transactivation by 45% and 25%, respectively, but did not abolish the induction. In murine PY41 endothelial cells, ETS2 and NERF-2 were the best transactivators, although again the degree of stimulation was weaker, probably because of endogenous Ets activity in these cells. In the endothelial cells, ELK, SAP, and Tel apparently down-regulate the basal activity of the promoter when compared with HEK293 cells. Deletion of the Transactivation studies were carried out using the murine PY41 endothelial cells. C) Because mutations made to the P1 and P2 doublet binding sequences significantly reduced basal promoter activity in the endothelial cells (see Fig. 3 ), these values are not normalized so as to indicate the loss of activity from the mutated constructs.
GT-rich region enhanced the induction and transactivation by ETS1, which occurred only when the GT-rich area was deleted (Fig. 4B) . Further deletion of the upstream Ets binding site decreased promoter activity back to wild-type levels (Fig. 4B) . Mutations of the P1 or P2 Ets doublet binding sites resulted in an almost complete loss of basal activity and transactivation capacity (Fig 4C) , indicating the importance of these binding sites in the Ets-induced activity of the Tie promoter.
Activity of Tie promoter constructs in transgenic mouse embryos
We showed earlier that the AflII-ApaI fragment of the mouse Tie promoter targets expression of heterologous genes specifically to endothelial cells in transgenic mice (4) . Deletion of the 541 bp AflII-BglII fragment from the 5Ј end of this promoter (cf. Fig.  2 ) was found to restrict the activity of the promoter to the bone marrow and lungs of transgenic mice (data not shown), indicating that some critical regions reside in the AflII-BglII fragment. To determine more specifically the DNA sequences critical for endothelial cell specificity in vivo, transgenic mouse embryos were produced and analyzed for ␤-galactosidase activity at 11.5 days postcoitum.
Deletion of the 5Ј region containing the GT repeats of Tie promoter did not affect endothelial cell specificity of the promoter. However, when the mTie prom-GT-Ets construct was tested in transgenic embryos, one of five injected embryos showed ␤-galactosidase activity throughout the endothelium (Fig. 5A) . The expression level in the endothelium of the positive embryo was comparable to that of ␤-galactosidase activity in the Tie/Tie-LacZ heterozygous knock-in embryos ( Fig. 5B ; see ref 20) , except in the heart endocardium, where only minor signals were obtained. Staining patterns in the various organs were confirmed by analysis of tissue sections. Intense blue staining was seen in the developing perineural/meningeal capillaries (Fig. 5C, D) as well as in the intersomitic arteries (Fig. 5E, F) in both mTie prom-GT-Ets transgenic and Tie/Tie-LacZ knock-in embryos. Blue staining was also observed in the endocardium of the heart ventricles in both cases (Fig. 5G, H) , although the staining was clearly much stronger in the heterozygous knock-in embryos. Mutation of the P2 doublet of Ets sites abolished most of the promoter activity. Five transgenic embryos made with this construct did not stain for ␤-galactosidase; only one embryo was found displaying weak staining of part of the vessels positive in mTie prom-GT-Ets embryo (Fig.  5A, inset) .
Tie promoter-driven secretion of hGH into blood circulation
Transgenic mice expressing the human growth hormone cDNA under the 0.8 kb Tie promoter were generated and analyzed as a model of Tie promoterdriven secretion of protein into the circulation, because the hGH levels can be easily quantitated in mice. The level of hGH in the serum from four mice was determined twice at the ages of 8 and 10 months by using hGH immunoradiometric assay, which does not cross-react with mouse GH. Results are presented in Table 1 . The amount of hGH in blood correlated with the copy number of the transgene, being between 0.25 and 1.04 mg/ml per one copy of the D, F, H) . Note that both reporter constructs produce a similar staining pattern in whole-mount embryos. The inset in panel A is one transgenic embryo injected with the mTie prom-GT-P2 construct showing reduced reporter gene expression. The endothelial cell-specific staining patterns in the various organs were confirmed by analysis of tissue sections. Intense blue staining was seen in the developing perineural/meningeal capillaries (C, D). Erythrocytes (e) could be seen inside the vessels lined with blue-staining endothelium between the cerebellar mesenchyme (cm) and the roof of the hindbrain (rh). ␤-Galactosidase activity was found also around the somitic cartilage (arrow, E, F) and in the intersomitic arteries (arrowheads, E, F). Blue staining was observed in the endocardium of the heart in both embryos, although the staining pattern was weaker in the mTie prom-GT-Ets transgenic embryo (G, H).
transgene. This suggested that the integration site of the transgene did not have a strong effect on the activity of the 0.8 kb promoter.
DISCUSSION
We have characterized the roles of the conserved DNA elements found in the mouse Tie promoter for its activity and endothelial cell specificity. A striking degree of endothelial cell specificity was observed in Tie promoter transfection experiments. In a previous study, when mainly HeLa cells were used, such specificity was not apparent in cultured cells. HeLa cells originate from a human cervical adenocarcinoma and express human papilloma virus early region genes, which can influence the regulation of the Tie promoter. Therefore, we used nontransformed mouse fibroblastic and epithelial cells in the present study. The endothelial cell-specific activity obtained in the reporter gene transfection experiments in cell culture is in line with results obtained using other endothelial-specific promoters (6, 10) .
Although the Tie promoter does not contain a TATA box, a single major transcription start site was obtained in RNase protection and primer extension analysis of embryonic and adult kidney RNA. Deletions made to the endothelial cell-specific AflII-ApaI fragment resulted in an inactive promoter, when the RNA start sites were included in the deleted fragments. These deletions also suggested that the P2 sequence containing putative Ets binding sites is responsible for much of the basal activity of the promoter in endothelial cells. Deletion of 0.6 kb containing the GT-rich region from the 5Ј end of the HindIII-NcoI Tie promoter fragment had opposite effects on promoter activity in two different endothelial cell lines, but it did not affect the endothelial cell specificity of the Tie promoter in vivo. The result that the GT element is not required for Tie promoter activity in endothelial cells is consistent with the finding that a similar fragment of the human Tie promoter does not contain a GT repeat (4). Additional 5Ј deletion, including the putative binding site for an Ets factor, did not markedly change the promoter activity in vitro, which suggests that Ets either does not bind to this site or that the binding is dispensable for promoter activity. The fact that this site is not conserved in the human sequence suggests that it is not a critical Ets binding site. Studies of Tie promoter-LacZ transgenic embryos gave further support for this view, as some transgenic embryos for mTie prom-GT-Ets/lacZ construct showed ␤-galactosidase activity specifically in the endothelial cells. However, a greater integration site dependency was seen with this construct, since ectopic expression was observed more frequently. In contrast, a mutation made in the octamer sequence, and especially the one in the P2 doublet of Ets sites in the 3Ј promoter region, reduced promoter activity dramatically in all cell lines studied, indicating the importance of these sequences for Tie promoter activity. Embryos transgenic for the mTie prom-GT-P2/lacZ construct had a strongly reduced reporter gene expression, confirming the critical role of these Ets sites for Tie promoter activity also in vivo.
Recently, an autonomous endothelial-specific enhancer in the first intron of the mouse Tek gene was characterized. In combination with the Tek promoter, this enhancer allowed targeting of gene expression to virtually all endothelial cells in mouse embryos (10) . The Tek enhancer contains many DNA elements that also occur in the Tie promoter. A mutation destroying the palindromic octamer and the putative NF-S site in the Tek enhancer caused greater integration site dependency of the corresponding construct. However, endothelial expression was only slightly weakened by this mutation. The same octamer sequence was also identified in the intercellular adhesion molecule 2 (ICAM-2) promoter region (12) . Human ICAM-2 expression in tissues is restricted largely to vascular endothelial cells and megakaryocytes (29) . A mutation of the octamer sequence reduced ICAM-2 promoter activity in bovine aortic endothelial cells by 70% (12) . Deletion of a Tek enhancer fragment containing solo and doublet Ets sites completely abolished in vivo activity of the Tek enhancer (10) . Because this enhancer contains only one Ets doublet element, the solo Ets site in this case may correspond to the P2 element rather than to the dispensable Ets site in the Tie promoter. The critical region of ICAM-2 promoter for endothelial cell-specific activity also contains a tandem Ets motif, but the significance of this region for promoter function remains to be determined. The essential function of Ets doublet elements in Tie and Tek promoters and their presence in the ICAM-2 promoter suggest that these sites are important for endothelial cell-specific gene transcription. To date, more than 30 Ets family members have been isolated from a variety of different species. Ets proteins are implicated in the regulation of gene expression during many important biological processes such as cell growth, differentiation and transformation. They all share a conserved 85 amino acid-long Ets domain. The Ets domain binding site contains a centrally located purine-rich sequence GGA (30) . Many different Ets proteins can bind to the same Ets binding site, and it has been suggested that the expression of specific Ets target genes in vivo is regulated by tissue-specific expression of particular Ets proteins. Among seven different members of the Ets transcription factor family tested, NERF-2 showed the strongest transactivation of the Tie promoter. NERF-2 is one of the three isoforms of NERF, which is a recently isolated member of the Ets factor family (31) . Among the Ets family, NERF has highest amino acid sequence homology to ELF-1, which is involved in the regulation of several T and B cell-specific genes (31) . NERF-2 has also been shown to transactivate Tek reporter constructs 15 to 20 fold (A. N. Dube et al., unpublished results), whereas the maximal transactivation of the Tie reporter construct was found to be eight-to ninefold in the present study. As NERF-2 is expressed in endothelial cells, it may also regulate Tie promoter activity in vivo. NERF-1a isoform, which is only weakly expressed in endothelial cells compared to NERF-2, was found to have no effect on Tie promoter activity. SAP1 and ELK-1 genes form a subgroup of the Ets family; they both interact with the serum response factor. However, neither SAP-1 nor ELK-1 transactivated Tie gene reporter constructs. ETS1 has a somewhat similar expression pattern as Tie (4, 32) . This proto-oncogene is transcribed in endothelia during angiogenesis in human and chick embryos, granulation tissue, and especially the endothelium of tumor vessels (32, 33) . Both ETS1 and ETS2 proteins can activate transcription through doublet Ets motifs and regulate transcription of genes encoding matrixdegrading proteases. In our experiments, ETS1 increased Tie promoter activity maximally by only three-to fourfold. Although one of the Ets factor gene knockouts (TEL) was recently reported to result in an extraembryonic vascular phenotype with abnormal vitelline vein development (34), it did not transactivate the Tie promoter. In conclusion, our results show that among the Ets factors tested, NERF-2 and ETS2 are the strongest transactivators of the Tie promoter, and that mutations made to all three putative Ets factor binding sites reduce significantly this transactivation capacity; the most striking reduction of both basal and Ets factor-induced activity was seen when either one of the Ets doublet elements was mutated. The contribution of other Ets factors in vascular development and Tie gene regulation remains to be determined, but it is highly likely that members of the Ets factor family play an important role given the conservation of Ets binding sites in several vascular-specific genes.
Angiogenesis is involved in many disease processes, including diabetes, psoriasis, and rheumatoid arthritis, as well as tumor growth and metastasis. One goal of studies of endothelial cell-specific promoters is to define elements that might be useful for pro-or antiangiogenic therapy. Another potentially useful application of endothelial cell-specific gene control elements is in the construction of vectors for endothelial cell-specific secretion of proteins replacing missing or nonfunctional gene products in the circulation. In this report, we tested the potential of the AflII-ApaI fragment of the mouse Tie promoter for such purposes, using a gene encoding the hGH marker protein that occurs in serum and can easily be quantitated. The Tie promoter-driven secretion of hGH was found to be relatively independent of the integration site, but dependent on transgene copy number. As high amounts of human growth hormone were detected in the circulation of transgenic mice, the Tie promoter may thus have potential for use in gene therapy.
